|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
86618 JD HEALTH-R
Nominal 
24.850 -0.600 (-2.358%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 28,343,961 | 4.550% | 53,529,941 | 46,736,150 | 30,682,267 | 19,382,568 |
| Cost of Sales | (21,644,018) | 3.524% | (41,664,605) | (36,844,642) | (23,484,985) | (14,465,270) |
| Gross Profit | 6,699,943 | 8.011% | 11,865,336 | 9,891,508 | 7,197,282 | 4,917,298 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 10,409 | -- | (69,859) | (98,202) | (38,352) | (17,539,975) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (40,806) | 26.739% | (70,757) | (96,759) | (94,165) | (77,024) | |
| Profit / (Loss) before Taxation | 2,439,342 | 33.208% | 2,693,348 | 695,809 | (901,491) | (17,072,141) | |
| Taxation | (404,964) | 50.413% | (550,468) | (312,580) | (171,327) | (162,756) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 2,804 | -- | (1,039) | (3,124) | (689) | 534 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,037,182 | 30.475% | 2,141,841 | 380,105 | (1,073,507) | (17,234,363) | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (985,491) | 5.732% | (1,939,547) | (855,167) | (451,570) | (145,700) |
| Depreciation & Amortisation | 103,218 | -4.366% | 227,458 | 140,676 | 63,169 | 27,221 |
| Directors' Emoluments | -- | -- | 418,439 | 664,846 | 1,062,758 | 296,370 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 65.000 | 30.000% | 69.000 | 12.000 | -35.000 | -780.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.474 | 1.901 | 1.109 | 1.675 |
| NBV per share ($) | 16.344 | -- | 15.479 | 14.082 | 12.475 | 12.326 |
| Remarks: | Real time quote last updated: 14/11/2024 15:17 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,037,182 |
| %Change | 30.475% |
| EPS / (LPS) | RMB 0.650 |
| NBV Per Share (¥) | RMB 16.344 |